CALGB 100103 - A Phase II Study of Allogeneic Transplant for Older Patients with AML In CRI Using a Non-Myeloablative Preparative Regimen.
CALGB 10403 - An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia
CALGB 10404 - A GENETIC RISK-STRATIFIED, RANDOMIZED PHASE II STUDY OF FOUR FLUDARABINE/ANTIBODY COMBINATIONS FOR PATIENTS WITH SYMPTOMATIC, PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
CALGB 10502 - Dose Escalation and Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years
CALGB 10503 - Phase II Study Of Maintenance Therapy With Decitabine (NSC #127716, IND #50733) Following Standard Induction And Cytogenetic Risk-Adapted Intensification In Previously Untreated Patients With AML Less Than 60 Years
CALGB 10602 - A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia
CALGB 10603 - Phase III Randomized Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
CALGB 29801 - Molecular and Cytogenetic Monitoring of CML
GCC 0447 - A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or Saha) In Combination with Cytosine Arabinoside (Ara-C) and Etoposide for Patients with Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders
GCC 0507 - A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
GCC 0835 - Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous
GCC 0854 - A Multicenter, Phase II Trial of Non-myeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies. BMT/CTN 0603
GCC 0908 - An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies
GCC0706 - Phase I Study of Sirolimus in Acute Myeloid Leukemia
GCC0753 - A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
GCC0754 - A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy
GCC0799 - A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
GCC0812 - Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-Consolidation Therapy in Adult Patients With Acute Myeloid Leukemia
GCC0844 - P04717 - A Phase 2 Study of SCH 727965 in Subjects with Relapsed and Refractory Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia
S0521 - A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low And Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
SWOG 0535 - A Phase II Study of Atra, Arsenic Trioxide And Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Email this Page
Print this Page
